These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9617980)

  • 1. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens.
    O'Hanlon JF; Robbe HW; Vermeeren A; van Leeuwen C; Danjou PE
    J Clin Psychopharmacol; 1998 Jun; 18(3):212-21. PubMed ID: 9617980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.
    Wingen M; Bothmer J; Langer S; Ramaekers JG
    J Clin Psychiatry; 2005 Apr; 66(4):436-43. PubMed ID: 15816785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
    Debonnel G; Saint-André E; Hébert C; de Montigny C; Lavoie N; Blier P
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):51-61. PubMed ID: 16690006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers.
    Siepmann T; Mueck-Weymann M; Oertel R; Kirch W; Pittrow D; Siepmann M
    Pharmacopsychiatry; 2008 Jul; 41(4):146-50. PubMed ID: 18651343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tianeptine and mianserin on car driving skills.
    Ridout F; Hindmarch I
    Psychopharmacology (Berl); 2001 Apr; 154(4):356-61. PubMed ID: 11349388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment.
    Riedel WJ; Eikmans K; Heldens A; Schmitt JA
    J Psychopharmacol; 2005 Jan; 19(1):12-20. PubMed ID: 15671124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor.
    Nathan PJ; Sitaram G; Stough C; Silberstein RB; Sali A
    Behav Pharmacol; 2000 Nov; 11(7-8):639-42. PubMed ID: 11198135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
    Blier P; Saint-André E; Hébert C; de Montigny C; Lavoie N; Debonnel G
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):41-50. PubMed ID: 16690005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of the dual mechanisms of action of venlafaxine.
    Harvey AT; Rudolph RL; Preskorn SH
    Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein.
    Abdelmawla AH; Langley RW; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1999 Sep; 48(3):345-54. PubMed ID: 10510145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psychopharmacological profile of venlafaxine].
    Bourin M
    Encephale; 1999 Jun; 25 Spec No 2():21-2; discussion 23-5. PubMed ID: 10434156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.
    Ramaekers JG
    J Clin Psychiatry; 2003 Jan; 64(1):20-9. PubMed ID: 12590619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition.
    Theunissen EL; Street D; Højer AM; Vermeeren A; van Oers A; Ramaekers JG
    Clin Pharmacol Ther; 2013 Jun; 93(6):493-501. PubMed ID: 23588319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans.
    Chial HJ; Camilleri M; Ferber I; Delgado-Aros S; Burton D; McKinzie S; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2003 May; 1(3):211-8. PubMed ID: 15017493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
    Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers.
    Hallam KT; Begg DP; Olver JS; Norman TR
    Hum Psychopharmacol; 2008 Mar; 23(2):129-37. PubMed ID: 18172907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressants.
    Frazer A
    J Clin Psychiatry; 1997; 58 Suppl 6():9-25. PubMed ID: 9227669
    [No Abstract]   [Full Text] [Related]  

  • 19. Concomitant use of tramadol and venlafaxine - evaluation of antidepressant-like activity and other behavioral effects in rats.
    Szkutnik-Fiedler D; Kus K; Balcerkiewicz M; Grześkowiak E; Nowakowska E; Burda K; Ratajczak P; Sadowski C
    Pharmacol Rep; 2012; 64(6):1350-8. PubMed ID: 23406745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venlafaxine marketed as antidepressant.
    Am J Hosp Pharm; 1994 Jul; 51(13):1606. PubMed ID: 7942885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.